Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival
Related Posts
Wang Y, Guan Y, Abbas AR, Sano Y, Jain S, Lu S, Hamidi H, Koeppen H, Azuma Y, Kayukawa Y, Shinozuka J, Pochiraju A, Webster[...]
Lee J, Zhao C, Yang J, Jonas SJ, Agopian V, You S, Posadas E, Yang JD, Zhu Y, Tseng HR. Tumor Extracellular Vesicle Digital Scoring[...]
Nishio M, Seto T, Reck M, Garon EB, Nishio K, Kasahara K, Nishino K, Satouchi M, Yoh K, Hayashi H, Sakai K, Enatsu S, Matsui[...]